| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7946ec4f3ab0ccdf6d369bf5079567ea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2004-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_618704f05679b6c726adce4bb0dc97fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2d9b603d66778b023b538229d8e8c7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9b7240574d84ce7b6187638ebe2d039
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35e02edb91718b7a70f828f73aca8de1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bfbd03e0497eb30202192fb73f81084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2837754a5c2f093600c636fefbcc24f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c69891c2c6f7c7a91c34ae957793519 |
| publicationDate |
2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2544532-A1 |
| titleOfInvention |
Compositions comprising polypeptides |
| abstract |
The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding sites specifically binds the human CD3 antigen. The polypeptide may exist in both monomeric form and multimeric form. The multimeric form of the polypeptide constitutes no more than 5% of the total weight of the combined monomeric and multimeric forms of said polypeptide. |
| priorityDate |
2003-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |